STSS Sharps Technology: Company Value to Revenue

Official company branding of Sharps Tech (STSS)

Sharps Technology, Inc. (STSS) management aims to optimize commercialization and curb capital expenditure. This EV/Revenue chart visualizes market expectations, where 6300.77 shows the value of this parameter. Assembly stability is guaranteed by diversified polymer supplies. Meanwhile, a strong engineering team, motivated by the social significance of safe syringes, provides the company with technological progress and creative potential.

Sharps Technology Inc (STSS): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 05/28/2026

STSS (Sharps Technology Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Initial company analysis:STSS (Sharps Technology Inc)
Manufactured products of Sharps Technology

This indicator compares the total enterprise value of Sharps Technology, Inc. (STSS) with its generated sales volume, excluding the impact of debt load. The metric determines the market premium paid per unit of revenue, reflecting investment expectations for scaling. The implementation of AI control and robotic packaging at Sharps Technology, Inc. (STSS) should accelerate revenue growth. By analyzing the historical EV/Sales trend, an investor can identify asset overvaluation. Peak values on this chart signal high risks in the event of a slowdown in expansion.

Competitor analysis for Sharps Technology, Inc.

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple